NLARx Newsletter Header
NLARx News
August 19, 2009
In This Issue
In the States
NLARx News
Outrage of the Week
Pharmaceuticals & Health Reform
Prices & Access
Fraud & Abuse
Patents & Generics
Conflicts of Interest
Advertising & Marketing
Pharma Watch
PBM Watch
Medicare & Medicaid
Reimportation
Electronic Records
Safety & Clinical Trials
Quick Links
Join Our Mailing List
In the States
MAINE: New Law Restricts Marketing to Minors More
VERMONT: State Enacts Strong Law on Physician Influence More
NEW HAMPSHIRE: Governor Signs Prescription Privacy Legislation More
WISCONSIN: Government Extends SeniorCare through 2012 More
Feds Extend Popular Drug Program for Seniors More
NORTH CAROLINA: Pharma Money Flows to Sway Health-Care Debate in North Carolina More
WEST VIRGINIA: State Extends Free Drug Program to 10,000 More More
NLARx News
Presentations from Two NLARx Panels at the NCLS Legislative Summit Now Online More
Outrage of the Week
Pfizer Investigator Stalked Neurontin Witness, Anonymous Donor Payed Off Plaintiffs More
Pharmaceuticals and Health Reform
Internal Memo Confirms Big Giveaways In White House Deal With Big Pharma More
White House Affirms Deal on Drug Cost More
Boehner Blasts PhRMA On Deal With White House More
PhRMA Tired of Talking About $80 Billion Deal More
PhRMA Statement on Commitment to Health Care Reform More
For Major Health Industry Players, Reform's Positives Outweigh Negatives More
What Can Drug Industry Expect from Health Reform in the Next Few Years? More
Prices and Access to Healthcare
White House Deal With Drug Industry Sparks Democratic Revolt More
Lawmakers Ask: What If Patients Shared in Medical Decisions? More
Prescription Drug Coverage Marred by Bureaucracy, Survey Says More
Free Meds for the Needy: Good Policy or Good PR? More
NEJM: Put Comparative Effectiveness on Drug Labels More
Comp. Effectiveness Promises Better, Cheaper Health Care But Critics Link It To Rationing More
House Panel Neuters Comparative Effectiveness More
Comparative Effectiveness Research and Evidence-Based Decision Making Across Four Countries: The U.K., Germany, France, and Australia More
Pfizer Agrees to Cut Price of TB Drug More
Fraud and Abuse
Medical Fraud Carries A Staggering Price Tag More
Allegran's Botox Problem More
Diet-Drug Lawyers Get 20, 25 Years for Stealing Funds More
State Zyprexa Deal in the Wings More
Patents and Generics
Drug Companies Resist White House Call to Reduce Rights to Exclusive Drug Data More
House Panel Passes Protection For Drug Makers More
GPhA Responds to House Energy and Commerce Committee Action on Biogenerics More
Lobbyists Battle Over Biologic Drug Protections More
GPhA Statement on House Energy and Commerce Committee Action on Patent Settlements More
Novartis, GSK in Vaccine Patent Fight More
Conflicts of Interest
Senator Moves to Block Medical Ghostwriting More
Medical Papers by Ghostwriters Pushed Therapy More
More On Ghostwriting, Wyeth and Hormone Replacement Therapy More
In Medical Publishing, Is Disclosure Enough? More
Drug Chief at the FDA Is Accused Of Conflict of Interest More
How Do You Ask Your Doctor if He Gets Paid by the Drug Industry? More
Lilly Details $22M in Doctor Payments More
Eli Lilly's Payments to Doctors Revealed More
Cutting the Bias: Senate Aging Committee Mulls Industry Funding of Continuing Medical Education More
New Group Seeks to Roll Back Conflict of Interest Regulations More
Advertising and Marketing
Medical Groups Promoted HPV Vaccine Using Drug Company Money More
Probing Doctors' Ties to Industry More
Saying 'No' to Drug Ads More
Privacy Rules Could Hinder Drug Marketing More
And You Thought a Prescription Was Private? More
How Will Cephalon Shift Patients to Nuvigil? More
Eyelash of the Beholder More
Pharma Watch
Novartis's Big Plans for Multiple Sclerosis More
GSK Chief Continues Humanitarian Crusade More
Branded Generics Hold Promise for Big Pharma More
PwC Foresees Drugmaker-Diagnostics Alliances More
New Diabetes Drug Could Give J &J's Januvia Stiff Competition More
Eli Lilly Seeking Buyouts for Hundreds in Sales Force More
PBM Watch
Battle Erupts Over Disclosure on Drug Prices More
Medco Suit: AstraZenca Bribed PBM to Have Drugs Remain on Formulary More
US, States Won't Intervene In PBM Fraud Lawsuit More
Express Scripts: No Rush to Close on WellPoint Unit More
Aetna to Sell Its PBM Unit More
Help for Seniors, Savings for All More
Reform Would Reveal Drugmaker-PBM Deals More
Medicare and Medicaid
Medicare Part D Premiums To Rise Slightly More
CMS on Premium Rates And Low-Income Subsidy Benchmarks For Medicare Prescription Drug Plans More
Procrit Kickback Case Goes Back to Court More
Brace Yourselves for Likely Medicaid Cuts More
Walgreen and Delaware Reach Medicaid Drug Deal More
ack of Medicare Appointee Puzzles Congress More
How Medicare Could Get Better Prices On Prescription Drugs More
New Article Examines Evidence and Lessons Learned From Medicare's Part D Drug Benefit More
Health Reform: Generic Biotech, Medicare Drug Prices More
Reimportation
The Deal to Block Reimportation and Medicare Drug Price Negotiations: What Really Happened? More
Cheaper Meds Are a Border Away More
Electronic Records
State Governments Join Push For Health IT More
Digital Health: Struggle or a Pipedream? More
Web System the Right Prescription? More
Five Lessons From Seattle On Adopting Electronic Medical Records More
In U.K., a Fight Over National Health IT System More
Safety and Clinical Trials
NIH Chief May Ask Pharmaceutical Companies to Pay Royalties on Federal Research More
FDA Chief: 'Violations Have Gone Unaddressed for Far Too Long' More
Gardasil, Cervarix face FDA next month More
More Bad News for Vytorin and Zetia? More
Merck Faces First of 900 Fosomax Cases More
FDA: Rheumatoid Arthritis Drugs Raise Cancer Risks for Kids More
Merck Tentatively Agrees to $80 Million Vioxx Settlement More
Pfizer Suit on Neurontin Is Dropped by Suicide Victim's Family More